Regional differences in short stature in England between 2006 and 2019: A cross-sectional analysis from the National Child Measurement Programme.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
09 2021
Historique:
received: 01 04 2021
accepted: 05 08 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 15 12 2021
Statut: epublish

Résumé

Short stature, defined as height for age more than 2 standard deviations (SDs) below the population median, is an important indicator of child health. Short stature (often termed stunting) has been widely researched in low- and middle-income countries (LMICs), but less is known about the extent and burden in high-income settings. We aimed to map the prevalence of short stature in children aged 4-5 years in England between 2006 and 2019. We used data from the National Child Measurement Programme (NCMP) for the school years 2006-2007 to 2018-2019. All children attending state-maintained primary schools in England are invited to participate in the NCMP, and heights from a total of 7,062,071 children aged 4-5 years were analysed. We assessed short stature, defined as a height-for-age standard deviation score (SDS) below -2 using the United Kingdom WHO references, by sex, index of multiple deprivation (IMD), ethnicity, and region. Geographic clustering of short stature was analysed using spatial analysis in SaTScan. The prevalence of short stature in England was 1.93% (95% confidence interval (CI) 1.92-1.94). Ethnicity adjusted spatial analyses showed geographic heterogeneity of short stature, with high prevalence clusters more likely in the North and Midlands, leading to 4-fold variation between local authorities (LAs) with highest and lowest prevalence of short stature. Short stature was linearly associated with IMD, with almost 2-fold higher prevalence in the most compared with least deprived decile (2.56% (2.53-2.59) vs. 1.38% (1.35-1.41)). There was ethnic heterogeneity: Short stature prevalence was lowest in Black children (0.64% (0.61-0.67)) and highest in Indian children (2.52% (2.45-2.60)) and children in other ethnic categories (2.57% (2.51-2.64)). Girls were more likely to have short stature than boys (2.09% (2.07-2.10) vs. 1.77% (1.76-1.78), respectively). Short stature prevalence declined over time, from 2.03% (2.01-2.05) in 2006-2010 to 1.82% (1.80-1.84) in 2016-2019. Short stature declined at all levels of area deprivation, with faster declines in more deprived areas, but disparities by IMD quintile were persistent. This study was conducted cross-sectionally at an area level, and, therefore, we cannot make any inferences about the individual causes of short stature. In this study, we observed a clear social gradient and striking regional variation in short stature across England, including a North-South divide. These findings provide impetus for further investigation into potential socioeconomic influences on height and the factors underlying regional variation.

Sections du résumé

BACKGROUND
Short stature, defined as height for age more than 2 standard deviations (SDs) below the population median, is an important indicator of child health. Short stature (often termed stunting) has been widely researched in low- and middle-income countries (LMICs), but less is known about the extent and burden in high-income settings. We aimed to map the prevalence of short stature in children aged 4-5 years in England between 2006 and 2019.
METHODS AND FINDINGS
We used data from the National Child Measurement Programme (NCMP) for the school years 2006-2007 to 2018-2019. All children attending state-maintained primary schools in England are invited to participate in the NCMP, and heights from a total of 7,062,071 children aged 4-5 years were analysed. We assessed short stature, defined as a height-for-age standard deviation score (SDS) below -2 using the United Kingdom WHO references, by sex, index of multiple deprivation (IMD), ethnicity, and region. Geographic clustering of short stature was analysed using spatial analysis in SaTScan. The prevalence of short stature in England was 1.93% (95% confidence interval (CI) 1.92-1.94). Ethnicity adjusted spatial analyses showed geographic heterogeneity of short stature, with high prevalence clusters more likely in the North and Midlands, leading to 4-fold variation between local authorities (LAs) with highest and lowest prevalence of short stature. Short stature was linearly associated with IMD, with almost 2-fold higher prevalence in the most compared with least deprived decile (2.56% (2.53-2.59) vs. 1.38% (1.35-1.41)). There was ethnic heterogeneity: Short stature prevalence was lowest in Black children (0.64% (0.61-0.67)) and highest in Indian children (2.52% (2.45-2.60)) and children in other ethnic categories (2.57% (2.51-2.64)). Girls were more likely to have short stature than boys (2.09% (2.07-2.10) vs. 1.77% (1.76-1.78), respectively). Short stature prevalence declined over time, from 2.03% (2.01-2.05) in 2006-2010 to 1.82% (1.80-1.84) in 2016-2019. Short stature declined at all levels of area deprivation, with faster declines in more deprived areas, but disparities by IMD quintile were persistent. This study was conducted cross-sectionally at an area level, and, therefore, we cannot make any inferences about the individual causes of short stature.
CONCLUSIONS
In this study, we observed a clear social gradient and striking regional variation in short stature across England, including a North-South divide. These findings provide impetus for further investigation into potential socioeconomic influences on height and the factors underlying regional variation.

Identifiants

pubmed: 34582440
doi: 10.1371/journal.pmed.1003760
pii: PMEDICINE-D-21-01543
pmc: PMC8478195
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003760

Subventions

Organisme : Wellcome Trust
ID : 108065/Z/15/Z
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Pediatr. 1994 Jul;125(1):29-35
pubmed: 8021781
Ann Hum Biol. 1990 Jan-Feb;17(1):1-6
pubmed: 2317001
J Clin Endocrinol Metab. 2013 May;98(5):2070-7
pubmed: 23533234
Acta Paediatr Jpn. 1987 Feb;29(1):96-103
pubmed: 3144856
J Epidemiol Community Health. 2020 Apr;74(4):336-345
pubmed: 31964723
Lancet Public Health. 2018 Apr;3(4):e194-e203
pubmed: 29571937
J Epidemiol Community Health. 2016 Feb;70(2):140-6
pubmed: 26359506
Lancet Diabetes Endocrinol. 2014 Oct;2(10):781-92
pubmed: 25009082
Public Health Nutr. 2014 Sep;17(9):2131-7
pubmed: 24477079
Horm Res Paediatr. 2016;85(5):325-32
pubmed: 27055026
Arch Dis Child. 2016 May;101(5):455-60
pubmed: 26883079
BMJ. 1994 Mar 5;308(6929):641-2
pubmed: 8148716
BMJ. 2010 Mar 15;340:c1140
pubmed: 20231247
Acta Paediatr. 2018 May 11;:
pubmed: 29750838
Lancet. 2020 Jan 4;395(10217):65-74
pubmed: 31852602
J Pediatr. 2005 Feb;146(2):212-6
pubmed: 15689911
Pediatrics. 2011 Apr;127(4):696-702
pubmed: 21422085
J Infect Dis. 2014 Jul 15;209 Suppl 3:S120-6
pubmed: 24966192
BMC Pediatr. 2007 Apr 10;7:17
pubmed: 17425787
Acta Paediatr Suppl. 2006 Apr;450:56-65
pubmed: 16817679
Matern Child Nutr. 2016 May;12 Suppl 1:12-26
pubmed: 27187907
Arch Dis Child. 2016 May;101(5):422-6
pubmed: 26342096
Arch Dis Child. 2004 Nov;89(11):1018-23
pubmed: 15499054

Auteurs

Joanna Orr (J)

Queen Mary University of London, London, United Kingdom.

Joseph Freer (J)

Queen Mary University of London, London, United Kingdom.

Joan K Morris (JK)

St George's University of London, London, United Kingdom.

Caroline Hancock (C)

Public Health England, London, United Kingdom.

Robert Walton (R)

Queen Mary University of London, London, United Kingdom.

Leo Dunkel (L)

Queen Mary University of London, London, United Kingdom.

Helen L Storr (HL)

Queen Mary University of London, London, United Kingdom.

Andrew J Prendergast (AJ)

Queen Mary University of London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH